鼻腔扩容术加腭咽成形术对阻塞睡眠呼吸暂停综合征的疗效分析

目的：研究分析临床应用鼻腔扩容术加腭咽成形术治疗阻塞睡眠呼吸暂停综合征的疗效。方法：选取2011年5月-2012年5月本院收治的15例阻塞睡眠呼吸暂停综合征患者,给予鼻腔扩容术加腭咽成形术联合治疗,分析其治疗后的临床疗效及并发症发生情况。结果：术后随访观察,6个月时治疗总有效率保持为100%,1年时治疗总有效率为93.3%,患者的AHI指数及LSaO2均较术前有明显改善,总体疗效满意;术后并发症发生率为46.7%,给予相应的对症治疗后症状消失,无实质性损害。结论：鼻腔扩容术联合腭咽成形术治疗阻塞睡眠呼吸暂停综合征近远期疗效均较满意,但术后并发症发生情况需进一步改善。     

Thermal Properties of Illite-Zeolite Mixtures up to 1100 °C

Illitic clays are the commonly used material in building ceramics. Zeolites are microporous, hydrated crystalline aluminosilicates, they are widely used due to their structure and absorption properties. In this study, illitic clay (Füzérradvány, Hungary) was mixed with natural zeolite (Nižný Hrabovec, Slovakia) with up to 50 wt.% of zeolite content. The samples were submitted to thermal analyses, such as differential thermal analysis, differential scanning calorimetry, thermogravimetry, and dilatometry. In addition, the evolution of thermal diffusivity, thermal conductivity, and specific heat capacity in the heating stage of firing were measured and discussed. The amount of the physically bound water in the samples increased along with the amount of zeolite. The temperature of the illite dehydroxylation (peak temperature) was slightly shifted to lower temperatures, from 609 °C to 575 °C (for sample IZ50). On the other hand, the mass loss and the shrinkage of the samples significantly increased with the zeolite content in the samples. Sample IZ50 reached 10.8% shrinkage, while the sample prepared only from the illitic clay contracted by 5.8%. Nevertheless, the temperature of the beginning of the sintering (taken from the dilatometric curves) decreased from 1021 °C (for illitic clay) to 1005 °C (for IZ50). The thermal diffusivity and thermal conductivity values decreased as the amount of zeolite increased in the samples, thus showing promising thermal insulating properties.     

Spatial spread and demographic expansion of Lyme borreliosis spirochaetes in Eurasia

The Lyme borreliosis (LB) group of spirochaetes currently comprises 18 named species that vary in their geographic distribution, host specificity and ability to cause disease in humans. In Europe three species are most abundant, Borrelia afzelii, Borrelia garinii and Borrelia valaisiana but only two of these (B. garinii and B. afzelii) are regularly found in Asia as well. A recently published study has shown that Borrelia species associated with birds, such as B. garinii, showed limited geographic structuring between European countries while, the rodent associated species, B. afzelii, showed extensive spatial structuring in Europe. Here, we use multilocus sequence analysis to show that when the wider, inter-continental, distribution is considered, there is evidence of spatial structuring even in the bird-associated species B. garinii. Furthermore, our investigations into historical LB populations provided evidence for range expansions of B. garinii and B. afzelii populations in Europe in the distant past. We propose that the expansion of B. afzelii in Europe may be linked to rodent population expansions after the last glacial maximum.     

Carlecortemcel-l: an ex vivo expanded umbilical cord blood cell graft for allogeneic transplantation

Background: Success of umbilical cord blood transplantation (UCBT) is mostly affected by the cell dose infused and its application is limited by the size of the recipient. For most adults and older children it is not possible to find a single UCB unit large enough for reliable engraftment. One strategy to increase the number of progenitor cells available is ex vivo expansion of the unit. The main challenge of ex vivo expansion systems is how not to deplete the self-renewing cell population by driving them into differentiation into committed progenitors. Objective: Copper modulates basic cell functions, such as survival, proliferation, and differentiation. Reduction of cellular copper in ex vivo culture conditions enabled preferential proliferation of early progenitors and increased engraftment capabilities. The result of a Phase I study of carlecortemcel-l, a product derived from ex vivo expansion of UCB progenitors in the presence of a copper chelator and early-acting cytokines, and the study design for the current pivotal study are presented. Methods: A literature review using PubMed and the investigator's brochure from the manufacturer. Conclusions: Early results suggest that carlecortemcel-l infusion is safe and may be associated with favorable non-relapse mortality rates. A pivotal global study is currently being conducted to evaluate safety and efficacy of this product from centralized manufacturing facilities.     

持续恒压快速扩张15例报告

目的　探讨一种简单易行的持续恒压快速皮肤软组织扩张术,并将扩张皮肤用于缺损的修复。方法　用普通输液器作注水装置向扩张囊内持续滴注的方法进行恒压无痛持续扩张,并改进了扩张器的注水部分,以使这种滴注扩张方便易行。结果　临床应用１５例（共２０只扩张器）。术后３～５天开始注水,平均注水时间为１０天,注水量为７０～２３０ｍｌ,注水结束７～１０天后进行扩张皮瓣转移术。皮瓣质量好。激光多普勒成像微循环扫描仪显示注水压力在未达痛阈水平之压力范围内（４０～１００ｃｍＨ２Ｏ）,其微循环与周围对照皮肤无明显变化。结论　持续滴注恒压扩张与常规扩张相比具有：扩张速度快,痛苦少,简单易行,安全可靠的优点。     

额部扩张皮瓣的手术设计

目的 探讨额部扩张皮瓣的手术设计。方法 对121例额、颞部瘢痕、斑痣、血管瘤等皮肤病变切除后的患者采用额部扩张皮瓣进行修复，并比较滑行皮瓣、易位皮瓣及旋转皮瓣的手术效果。结果 115例患者取得良好的手术效果，修复后皮肤弹性良好、颜色较理想、瘢痕较细小；4例患者扩张皮瓣的远端有0．5～1．0cm的坏死，行Ⅱ期瘢痕切除缝合术；2例患者有单侧眉上提，半年后好转。结论 易位皮瓣术后瘢痕明显，尽量少用或不用；旋转皮瓣可以充分利用扩张后“过剩”的皮肤。是一种值得推广的额部皮瓣设计方法。对皮瓣的周密设计并了解不同皮瓣的优缺点。对手术效果及术后并发症的预防非常重要。     

皮肤软组织扩张术在头皮缺损伴颅骨外露修复中的应用

目的 探讨外伤致大面积头皮缺损后的肉芽组织创面伴颅骨外露的修复方法.方法 对外伤后头皮缺损肉芽组织创面伴颅骨外露8例患者,在形成新鲜肉芽组织创面后于正常头皮帽状腱膜下埋置皮肤软组织扩张器12只,术中以及注水扩张过程中严格无菌操作,适度扩张,保持扩张部位丰富的血液循环.扩张满意后取出皮肤软组织扩张器行扩张后皮瓣修复创面.结果 8例患者均完成头皮缺损创面的修复,扩张器埋置术后以及注水扩张过程中未见感染.结论 皮肤软组织扩张术可以修复外伤头皮缺损后肉芽组织创面伴颅骨外露.     

Collar Badge Lens Dose Equivalent Values among United States Physicians Performing Fluoroscopically Guided Interventional Procedures

PurposeTo describe the range of occupational badge dose readings and annualized dose records among physicians performing fluoroscopically guided interventional (FGI) procedures using job title information provided by the same 3 major medical institutions in 2009, 2012, and 2015.Materials and MethodsThe Radiation Safety Office of selected hospitals was contacted to request assistance with identifying physicians in a large commercial dosimetry database. All entries judged to be uninformative of occupational doses to FGI procedure staff were excluded. Monthly and annualized doses were described with univariate statistics and box-and-whisker plots.ResultsThe dosimetry data set of interventional radiology staff contained 169 annual dose records from 77 different physicians and 698 annual dose records from 455 nonphysicians. The median annualized lens dose equivalent values among physicians (11.9 mSv; interquartile range [IQR], 6.9–20.0 mSv) was nearly 3-fold higher than those among nonphysician medical staff assisting with FGI procedures (4.0 mSv; IQR, 1.8–6.7 mSv) (P < .001). During the study period, without eye protection, 25% (23 of 93) of the physician annualized lens dose equivalent values may have exceeded 20 mSv; for nonphysician medical staff, this value may have been exceeded 3.5% (6 of 173) of the time. However, these values did not account for eye protection.ConclusionsThe findings from this study highlight the importance of mitigating occupational dose to the eyes of medical staff, particularly physicians, performing or assisting with FGI procedures. Training on radiation protection principles, the use of personal protective equipment, and patient radiation dose management can all help ensure that the occupational radiation dose is adequately controlled.     

Comparison of Foaming Properties Between the Shirasu Porous Glass Membrane Device and Tessari’s Three-way Stopcock Technique for Polidocanol and Ethanolamine Oleate Foam Production: A Benchtop Study

PurposeTo compare the characteristics of polidocanol (POL) and ethanolamine oleate (EO) sclerosing foams produced by a Shirasu porous glass membrane (SPGM) device with those made using a 3-way stopcock (3WSC).Materials and MethodsFoam half-life times were measured in an ex-vivo benchtop study. Computed tomography (CT) images of each foam were obtained over the time course, and a CT texture analysis was conducted. The bubble size in each foam was measured by an optical microscope.ResultsMedian foam half-life times were longer in the SPGM group than in the 3WSC group (POL: 198 vs 166 s, P = .02; EO: 640 vs 391 s, P < .01). In the CT texture analysis, median standard deviation (SD) and entropy (randomness) were lower, and median energy (uniformity) and gray-level cooccurrence matrix (GLCM) homogeneity were higher in the SPGM group than in the 3WSC group (POL SD: at 30 s and 50–300 s; POL entropy: at 0–60 s; EO SD: at 0–600 s; EO entropy: at 0–460 s; POL energy: at 0–40 s; POL GLCM homogeneity: at 0–250 s; EO energy: at 0–360 s; EO GLCM homogeneity: at 0–480 s; all P < .05). Median bubble diameters in the SPGM group and in the 3WSC group were 69 and 83 μm (P < .01), respectively, in the POL foam; and 36 and 36 μm (P = .45), respectively, in the EO foam.ConclusionsPOL and EO foams had greater uniformity and longer foam half-life time when prepared with an SPGM device than with a 3WSC.     

Pharmacokinetics and Early Tumor Response to Conventional Transarterial Chemoembolization with Sorafenib and Doxorubicin in a VX2 Rabbit Tumor Model

PurposeTo investigate the pharmacokinetics (PK) and early effects of conventional transarterial chemoembolization (TACE) using sorafenib and doxorubicin on tumor necrosis, hypoxia markers, and angiogenesis in a rabbit VX2 liver tumor model.Materials and MethodsVX2 tumor-laden New Zealand White rabbits (N = 16) were divided into 2 groups: 1 group was treated with hepatic arterial administration of ethiodized oil and doxorubicin emulsion (DOX-TACE), and the other group was treated with ethiodized oil, sorafenib, and doxorubicin emulsion (SORA-DOX-TACE). Animals were killed within 3 days of the procedure. Levels of sorafenib and doxorubicin were measured in blood, tumor, and adjacent liver using mass spectrometry. Tumor necrosis was determined by histopathological examination. Intratumoral hypoxia-inducible factor (HIF) 1α, vascular endothelial growth factor (VEGF), and microvessel density (MVD) were determined by immunohistochemistry.ResultsThe median intratumoral concentration of sorafenib in the SORA-DOX-TACE group was 17.7 μg/mL (interquartile range [IQR], 7.42–33.5 μg/mL), and its maximal plasma concentration (C_max) was 0.164 μg/mL (IQR, 0.0798–0.528 μg/mL). The intratumoral concentration and C_max of doxorubicin were similar between the groups: 4.08 μg/mL (IQR, 3.18–4.79 μg/mL) and 0.677 μg/mL (IQR, 0.315–1.23 μg/mL), respectively, in the DOX-TACE group and 1.68 μg/mL (IQR, 0.795–4.08 μg/mL) and 0.298 μg/mL (IQR, 0.241–0.64 μg/mL), respectively, in the SORA-DOX-TACE group. HIF-1α expression was increased in the SORA-DOX-TACE group than in the DOX-TACE group. Tumor volume, tumor necrosis, VEGF expression, and MVD were similar between the 2 groups.ConclusionsThe addition of sorafenib to DOX-TACE delivered to VX2 liver tumors resulted in high intratumoral and low systemic concentrations of sorafenib without altering the PK of doxorubicin.